For research use only. Not for therapeutic Use.
Suriclone（Cat No.:I009652）is a drug that belongs to the class of selective serotonin receptor antagonists, primarily developed for its potential use in the treatment of mood disorders and anxiety. It works by blocking specific serotonin receptors, which may help balance serotonin levels in the brain, thus alleviating symptoms of anxiety and depression. Suriclone has shown promise in preclinical studies for its ability to modulate serotonin activity without the sedative effects often seen with other serotonergic drugs. However, its safety, efficacy, and clinical applications require further research and clinical trials for validation.
| Catalog Number | I009652 |
| CAS Number | 53813-83-5 |
| Synonyms | Suriclone; RP 31264; RP-31264; RP31264;6-(7-chloro-1,8-naphthyridin-2-yl)-7-oxo-2,3,6,7-tetrahydro-5H-[1,4]dithiino[2,3-c]pyrrol-5-yl 4-methylpiperazine-1-carboxylate |
| Molecular Formula | C20H20ClN5O3S2 |
| Purity | ≥95% |
| Target | GABA-A Receptor Agonist |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4°C for short term , or -20°C for long term. |
| IUPAC Name | [6-(7-chloro-1,8-naphthyridin-2-yl)-5-oxo-3,7-dihydro-2H-[1,4]dithiino[2,3-c]pyrrol-7-yl] 4-methylpiperazine-1-carboxylate |
| InChI | InChI=1S/C20H20ClN5O3S2/c1-24-6-8-25(9-7-24)20(28)29-19-16-15(30-10-11-31-16)18(27)26(19)14-5-3-12-2-4-13(21)22-17(12)23-14/h2-5,19H,6-11H2,1H3 |
| InChIKey | RMXOUBDDDQUBKD-UHFFFAOYSA-N |
| SMILES | CN1CCN(CC1)C(=O)OC2C3=C(C(=O)N2C4=NC5=C(C=C4)C=CC(=N5)Cl)SCCS3 |
| Reference | </br>1:Acute effects of the anxiolytics suriclone and alprazolam on cognitive information processing utilizing topographic mapping of event-related brain potentials (P300) in healthy subjects. Semlitsch HV, Anderer P, Saletu B.Eur J Clin Pharmacol. 1995;49(3):183-91. PMID: 8665994 </br>2:Pharmacokinetic and -dynamic studies with a new anxiolytic, suriclone, utilizing EEG mapping and psychometry. Saletu B, Grünberger J, Linzmayer L, Semlitsch HV, Anderer P, Chwatal K.Br J Clin Pharmacol. 1994 Feb;37(2):145-56. PMID: 7910470 Free PMC Article</br>3:Pharmacokinetic and pharmacodynamic study of suriclone imipramine interaction in man. Perault MC, Chapelle G, Bouquet S, Chevalier P, Montay G, Gaillot J, Chakroun H, Guillet P, Vandel B.Fundam Clin Pharmacol. 1994;8(3):251-5. PMID: 7927120 </br>4:Suriclone enhances the actions of chlorpromazine on human psychomotor performance but not on memory or plasma prolactin in healthy subjects. Mattila MJ, Vanakoski J, Mattila-Evenden ME, Karonen SL.Eur J Clin Pharmacol. 1994;46(3):215-20. PMID: 7915235 </br>5:The pharmacokinetics of suriclone after single- and multiple-dose administration in healthy elderly volunteers. Crome P, Wijayawardhana P, Ankier SI, Dowell P, Chevalier P, Guillet P.Drugs Aging. 1993 Sep-Oct;3(5):436-40. PMID: 7902144 </br>6:High-performance liquid chromatographic assay with diode-array detection for toxicological screening of zopiclone, zolpidem, suriclone and alpidem in human plasma. Tracqui A, Kintz P, Mangin P.J Chromatogr. 1993 Jun 23;616(1):95-103. PMID: 8104192 </br>7:Effect of the cyclopyrrolones suriclone and RP 59037 on body temperature in mice. Jackson HC, Ramsay E, Nutt DJ.Eur J Pharmacol. 1992 May 27;216(1):23-7. PMID: 1356087 </br>8:The effects of acute and repeated doses of suriclone on subjective sleep, psychomotor performance and cognitive function in young and elderly volunteers. Gilburt SJ, Fairweather DB, Kerr JS, Hindmarch I.Fundam Clin Pharmacol. 1992;6(6):251-8. PMID: 1362556 </br>9:The interactions of ethanol with single and repeated doses of suriclone and diazepam on physiological and psychomotor functions in normal subjects. Allen D, Lader M.Eur J Clin Pharmacol. 1992;42(5):499-505. PMID: 1351467 </br>10:Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam, and placebo in generalized anxiety disorder. Ansseau M, Olié JP, von Frenckell R, Jourdain G, Stehle B, Guillet P.Psychopharmacology (Berl). 1991;104(4):439-43. PMID: 1685793 |
